Optimera strategier för retention, varaktighet och avbrytande av läkemedelsbehandling med opioidanvändning (RDD)
NIDA-CTN-0100: Optimering av strategier för retention, varaktighet och avbrytande av opioidanvändningsstörning (RDD)
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
The main objectives of this study are:
- To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
- To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
- To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.
The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
-
-
California
-
Tarzana, California, Förenta staterna, 91356
- Tarzana Treatment Centers, Inc.
-
-
Connecticut
-
Bridgeport, Connecticut, Förenta staterna, 06610
- Liberation Programs, Inc.
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33760
- Operation PAR
-
Jacksonville, Florida, Förenta staterna, 32204
- Gateway Community Services
-
Orlando, Florida, Förenta staterna, 32806
- Aspire Health Partners
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21229
- Mountain Manor / Maryland Treatment Centers
-
-
Massachusetts
-
Belmont, Massachusetts, Förenta staterna, 02478
- McLean Hospital
-
Fall River, Massachusetts, Förenta staterna, 02720
- Stanley Street Treatment and Resources, Inc.
-
Newton, Massachusetts, Förenta staterna, 02458
- Square Medical Group, LLC
-
-
Missouri
-
Cape Girardeau, Missouri, Förenta staterna, 63703
- Gibson Center for Behavioral Change
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03766
- Dartmouth Hitchcock - ATP
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- University of New Mexico Addiction and Substance Abuse Program
-
-
New York
-
New York, New York, Förenta staterna, 10016
- Bellevue Hospital Center
-
-
Oregon
-
Roseburg, Oregon, Förenta staterna, 97470
- Adapt Integrated Health Care
-
Winston, Oregon, Förenta staterna, 97496
- Adapt Integrated Health Care
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Center for Psychiatric and Chemical Dependency Services (CPCDS)
-
Pittsburgh, Pennsylvania, Förenta staterna, 15219
- Internal Medicine Recovery Engagement Program (IM-REP)
-
-
South Carolina
-
Conway, South Carolina, Förenta staterna, 29526
- Shoreline Behavioral Health Services
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84108
- Huntsman Mental Health Institute / University of Utah
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26505
- Chestnut Ridge Center
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria for Retention Phase:
- 18 years of age or older;
- Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
- Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
- If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
- Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
- In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
- Willing and able to provide written informed consent;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Retention Phase:
-
Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
- Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
Known allergy or sensitivity to preferred medication or its components;
-
Maintenance on methadone at the time of signing consent;
-
For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;
-
For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).
Inclusion Criteria for Discontinuation Phase:
- 18 years of age or older;
- Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
- Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
- Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
- If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
- Willing to be randomized to either MM or to MMD;
- Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Discontinuation Phase:
-
Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;
-
Meets current DSM-5 criteria for any current alcohol use disorder;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Retention: SL-BUP standard dose + MM
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentell: Retention: SL-BUP high dose + MM
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentell: Retention: XR-BUP + MM
Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
|
|
Experimentell: Retention: XR-NTX + MM
Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Andra namn:
|
|
Experimentell: Retention: SL-BUP standard dose + MMR
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Retention: SL-BUP high dose + MMR
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Retention: XR-BUP + MMR
Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Retention: XR-NTX + MMR
Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Andra namn:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Discontinuation: Discontinue SL-BUP with SL-BUP + MM
Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentell: Discontinuation: Discontinue SL-BUP with XR-BUP + MM
Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
|
|
Experimentell: Discontinuation: Discontinue XR-BUP with XR-BUP + MM
Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
|
|
Experimentell: Discontinuation: Discontinue XR-NTX with XR-NTX + MM
Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Andra namn:
|
|
Experimentell: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD
Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Andra namn:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD
Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD
Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Andra namn:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentell: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD
Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Andra namn:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Retention: Continuous retention in MOUD treatment through 26 weeks
Tidsram: Retention: from randomization through week 26
|
Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period. |
Retention: from randomization through week 26
|
|
Discontinuation: Completed Discontinuation without Relapse
Tidsram: Discontinuation: from randomization through week 24 follow up
|
Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued. |
Discontinuation: from randomization through week 24 follow up
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Retention KS1: Weekly opioid abstinence
Tidsram: Retention: from randomization through week 26
|
Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26. |
Retention: from randomization through week 26
|
|
Retention KS2: Treatment effectiveness
Tidsram: Retention: at week 26
|
Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26. |
Retention: at week 26
|
|
Retention KS3: Treatment by baseline severity
Tidsram: Retention: at week 26
|
Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no). |
Retention: at week 26
|
|
Discontinuation KS1: Completed Discontinuation
Tidsram: Discontinuation: from randomization through week 24 follow up
|
Completed Discontinuation without regard to relapse status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS2: Relapse
Tidsram: Discontinuation: from randomization through week 24 follow up
|
Relapse - separate binary outcome without regard to discontinuation status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS3: Safety
Tidsram: Discontinuation: from randomization through week 24 follow up
|
Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal. |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS4: Treatment effectiveness
Tidsram: Discontinuation: at end of taper (EoT) and week 24 follow up
|
Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint). |
Discontinuation: at end of taper (EoT) and week 24 follow up
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Utredare
Utredare
- Huvudutredare: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
- Huvudutredare: Roger Weiss, MD, Harvard Medical School/McLean Hospital
- Huvudutredare: John Rotrosen, MD, NYU Langone Health
Publikationer och användbara länkar
Allmänna publikationer
- Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemp Clin Trials. 2025 Mar;150:107816. doi: 10.1016/j.cct.2025.107816. Epub 2025 Jan 20.
- Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemp Clin Trials. 2024 Jul;142:107543. doi: 10.1016/j.cct.2024.107543. Epub 2024 Apr 23.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Narkotikarelaterade störningar
- Mentala störningar
- Substansrelaterade störningar
- Kemiskt inducerade störningar
- Opioidrelaterade störningar
- Heterocykliska föreningar
- Heterocykliska föreningar, smältring
- Farmaceutiska förberedelser
- Alkaloider
- Polycykliska aromatiska kolväten
- Polycykliska föreningar
- Heterocykliska föreningar, 4 eller fler ringar
- Narkotikakombinationer
- Naloxon
- Morfiner
- Opiatalkaloider
- Heterocykliska föreningar, överbryggad ring
- Fenanträn
- Buprenorfin, Naloxon Läkemedelskombination
- Buprenorfin
- vivitrol
Andra studie-ID-nummer
Andra studie-ID-nummer
- 19-01363
- UG1DA015831 (U.S.S. NIH-anslag/kontrakt)
- CTN-0100 (Annan identifierare: NIDA Clinical Trials Network)
- UG1DA013035 (U.S.S. NIH-anslag/kontrakt)
- 20-PRS-057 (Annan identifierare: Biomedical Research Alliance of New York (BRANY) sIRB)
- 146193 (Annan identifierare: FDA/IND#)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).
Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.
The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).
Tidsram för IPD-delning
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .